ReviewWorld journal of microbiology & biotechnology2026
Production and functional applications of fructooligosaccharides and their core bioactive components.
Review in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in Enzymatic Production of Prebiotic Oligosaccharides from Agro-Industrial Waste: A Critical Review and Industrial Framework.Foods (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Fructooligosaccharides (FOS) are widely recognized as functional prebiotics with diverse physiological activities, including modulation of the gut microbiota, anti-diabetic effects, enhancement of immune responses, and other health promoting functions. Based on their terminal residues, FOS can be classified into fructose-terminated fructooligosaccharides (Fn, n = 2 ~ 9) and glucose-terminated fructooligosaccharides (GFn, n = 2 ~ 8). Compared with Fn, GFn exhibit distinct advantages in terms of raw material availability, production processes, manufacturing costs, and application potential, and therefore have received more attention. Among GFn, kestoses (GF2), nystose (GF3), and fructosylnystose (GF4) represent the core bioactive components and display distinct physiological effects. This review critically summarizes the current advances in the production and purification techniques of GFn mixtures and their core components (GF2, GF3 and GF4), with particular emphasis on 1-kestose due to its superior efficacy in gut microbiota modulation, aiming to provide valuable insights to support future production, application and development.
Indexed as
Identifiers
41961431What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.